MX2020007956A - Inhibidores de la proteína de unión al elemento regulador de esterol (srebp) que comprenden un anillo central de 6 miembros. - Google Patents

Inhibidores de la proteína de unión al elemento regulador de esterol (srebp) que comprenden un anillo central de 6 miembros.

Info

Publication number
MX2020007956A
MX2020007956A MX2020007956A MX2020007956A MX2020007956A MX 2020007956 A MX2020007956 A MX 2020007956A MX 2020007956 A MX2020007956 A MX 2020007956A MX 2020007956 A MX2020007956 A MX 2020007956A MX 2020007956 A MX2020007956 A MX 2020007956A
Authority
MX
Mexico
Prior art keywords
formula
srebp
compounds
central ring
tautomers
Prior art date
Application number
MX2020007956A
Other languages
English (en)
Inventor
Michael John Green
Barry Patrick Hart
Original Assignee
Capulus Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capulus Therapeutics Llc filed Critical Capulus Therapeutics Llc
Publication of MX2020007956A publication Critical patent/MX2020007956A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan en la presente compuestos que comprenden un núcleo de tres anillos, tales como compuestos de Fórmula (X), Fórmula (X-A), Fórmula (X-Ai), Fórmula (X-B), Fórmula (X-Bi), Fórmula (Z), Fórmula (Z-A), Fórmula (Z-Ai), Fórmula (Z-B), Fórmula (Z-Bi), Fórmula (I), Fórmula (IA), Fórmula (I-Ai), Fórmula (I-B), y Fórmula (I-Bi), y sales, solvatos, tautómeros, isótopos, o isómeros farmacéuticamente aceptables de los mismos; también se proporcionan en la presente métodos para inhibir un componente de la trayectoria de la proteína de unión al elemento regulador de esterol (SREBP), tal como una proteína de activación de disociación de SREBP o SREBP (SCAP), utilizando estos compuestos, o sales, solvatos, tautómeros, isótopos, o isómeros farmacéuticamente aceptables de los mismos; se proporcionan además métodos de tratamiento de un trastorno en un sujeto en necesidad del mismo, tal como enfermedad hepática, esteatohepatitis no alcohólica, resistencia a la insulina, o cáncer. (Ver Fórmulas).
MX2020007956A 2018-01-29 2019-01-28 Inhibidores de la proteína de unión al elemento regulador de esterol (srebp) que comprenden un anillo central de 6 miembros. MX2020007956A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862623405P 2018-01-29 2018-01-29
US201862744397P 2018-10-11 2018-10-11
PCT/US2019/015458 WO2019148125A1 (en) 2018-01-29 2019-01-28 Srebp inhibitors comprising a 6-membered central ring

Publications (1)

Publication Number Publication Date
MX2020007956A true MX2020007956A (es) 2021-01-08

Family

ID=67395734

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007956A MX2020007956A (es) 2018-01-29 2019-01-28 Inhibidores de la proteína de unión al elemento regulador de esterol (srebp) que comprenden un anillo central de 6 miembros.

Country Status (13)

Country Link
US (1) US11718628B2 (es)
EP (1) EP3746070A4 (es)
JP (1) JP2021512160A (es)
KR (1) KR20200128531A (es)
CN (1) CN112243374A (es)
AU (1) AU2019212959A1 (es)
BR (1) BR112020015375A2 (es)
CA (1) CA3089134A1 (es)
IL (1) IL276276A (es)
MX (1) MX2020007956A (es)
SG (1) SG11202006853PA (es)
TW (1) TW201940165A (es)
WO (1) WO2019148125A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020015375A2 (pt) 2018-01-29 2020-12-08 Capulus Therapeutics, Llc Inibidores de srebp compreendendo um anel central de seis membros
EP3942048A1 (en) 2019-03-20 2022-01-26 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors
CN110628737B (zh) * 2019-10-14 2022-06-07 南京农业大学 一个调控黄瓜矮化性状相关基因及其应用
EP4058016A4 (en) * 2019-11-13 2023-12-20 Capulus Therapeutics, LLC THIOPHENE COMPOUNDS WITH CYCLIC AMIDES AND USES THEREOF
CN111139294A (zh) * 2020-01-06 2020-05-12 中国药科大学 Fdps在制备治疗非酒精性脂肪性肝炎药物中的应用
EP4185584A1 (en) * 2020-07-24 2023-05-31 Capulus Therapeutics, LLC Srebp inhibitors comprising a thiophene central ring

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
EP1608622A4 (en) * 2003-03-24 2009-04-01 Merck & Co Inc BIARYLSUBSTITUTED 6-LOW HETEROCYCLES AS SODIUM CHANNEL BLOCKERS
AU2006261841B8 (en) 2005-06-27 2012-12-06 Exelixis Patent Company Llc Pyrazole based LXR modulators
CN101213183A (zh) * 2005-06-30 2008-07-02 惠氏公司 氨基-5-(6元)杂芳基咪唑酮化合物和在β-分泌酶调节中的用途
TW200825054A (en) * 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
GB0625659D0 (en) * 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
US8207196B2 (en) 2007-02-02 2012-06-26 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9212179B2 (en) 2007-02-02 2015-12-15 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US9233941B2 (en) 2007-02-02 2016-01-12 Baylor College Of Medicine Methods and compositions for the treatment of body weight related disorders
US20160221999A1 (en) 2007-02-02 2016-08-04 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
JPWO2009131173A1 (ja) * 2008-04-23 2011-08-18 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
US8563583B2 (en) 2009-03-09 2013-10-22 Bristol-Myers Squibb Company Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
US8962623B2 (en) 2011-03-04 2015-02-24 Locus Pharmaceuticals, Inc. Aminopyrazine compounds
CA2863515C (en) * 2012-01-31 2018-02-27 Daiichi Sankyo Company, Limited Pyridone derivatives
WO2013162061A1 (ja) * 2012-04-26 2013-10-31 第一三共株式会社 二環性ピリミジン化合物
US10038143B2 (en) * 2012-09-14 2018-07-31 Idemitsu Kosan Co., Ltd. Polymer compound, material for electronic elements, material for organic electroluminescent elements, and organic electroluminescent element
CN103405429A (zh) * 2013-08-22 2013-11-27 中国药科大学 一类vegfr-2抑制剂及其用途
SG10201806370QA (en) * 2013-08-28 2018-08-30 Medivation Tech Llc Heterocyclic compounds and methods of use
CU24425B1 (es) 2013-11-01 2019-06-04 Novartis Ag Amino-heteroaril-benzamidas como inhibidores de cinasa
JP6454727B2 (ja) * 2014-04-24 2019-01-16 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピリジン誘導体
TWI690525B (zh) * 2014-07-07 2020-04-11 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
WO2016073826A1 (en) 2014-11-07 2016-05-12 Fgh Biotech, Inc. Synthesis of fatostatin based polycyclic compounds
US10328064B2 (en) * 2014-12-23 2019-06-25 Fgh Biotech, Inc. Compositions of fatostatin based heterocyclic compounds and uses thereof
EP3265457A1 (en) * 2015-03-04 2018-01-10 Medivation Technologies LLC Sterol regulatory element-binding proteins (srebps) inhibitors
JP2018507234A (ja) * 2015-03-04 2018-03-15 メディベイション テクノロジーズ エルエルシー 肝臓線維症、コレステロールの上昇およびインスリン抵抗性を処置する際における使用のためのｓｒｅｂｐ遮断薬
EP3448851B8 (en) * 2016-04-29 2022-04-27 FGH BioTech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
US11400082B2 (en) 2017-10-30 2022-08-02 Montréal Heart Institute Methods of treating elevated plasma cholesterol
RU2020124116A (ru) 2017-12-22 2022-01-25 Хиберселл, Инк. Производные арил-бипиридинамина в качестве ингибиторов фосфатидилинозитолфосфаткиназы
BR112020015375A2 (pt) 2018-01-29 2020-12-08 Capulus Therapeutics, Llc Inibidores de srebp compreendendo um anel central de seis membros
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
EP3917513A4 (en) 2019-01-28 2022-11-09 Capulus Therapeutics, LLC SREBP INHIBITORS WITH A THIOPHENE CENTER RING
SG11202108636SA (en) 2019-02-11 2021-09-29 Merck Patent Gmbh Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer
MX2022005826A (es) 2019-11-13 2022-08-16 Capulus Therapeutics Llc Inhibidor de srebp que comprende un anillo central de tiofeno.

Also Published As

Publication number Publication date
EP3746070A4 (en) 2021-09-01
AU2019212959A1 (en) 2020-09-17
CN112243374A (zh) 2021-01-19
BR112020015375A2 (pt) 2020-12-08
JP2021512160A (ja) 2021-05-13
EP3746070A1 (en) 2020-12-09
KR20200128531A (ko) 2020-11-13
US11718628B2 (en) 2023-08-08
SG11202006853PA (en) 2020-08-28
IL276276A (en) 2020-09-30
WO2019148125A1 (en) 2019-08-01
TW201940165A (zh) 2019-10-16
US20210047340A1 (en) 2021-02-18
CA3089134A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
MX2020007956A (es) Inhibidores de la proteína de unión al elemento regulador de esterol (srebp) que comprenden un anillo central de 6 miembros.
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
SG11202100137TA (en) PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8
MX2022001421A (es) Compuesto tetracíclico, método de preparación y uso del mismo.
MX2022006609A (es) Compuesto de quinazolina que contiene anillo espiro.
SG11202100130QA (en) Pyridine carboxamide compounds for inhibiting nav1.8
MX2018003861A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
MX2017008417A (es) Procedimientos para preparar inhibidores de cinasa 1 reguladora de señal de apoptosis (ask1).
SI4003989T1 (sl) 6,7-dihidro-5H-pirido(2,3-c)piridazinski derivati in sorodne spojine kot inhibitorji Bcl-xL proteina in proapoptotična sredstva za zdravljenje raka
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
AR096758A1 (es) Inhibidores cristalinos de bromodominios
MX2023003792A (es) Uso de compuestos de cloroquina y clemizol para el tratamiento de afecciones inflamatorias y cancerosas.
WO2020159889A9 (en) Srebp inhibitors comprising a thiophene central ring
MX2019014021A (es) Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo.
SG11201906435SA (en) Pyrimidine compound and pharmaceutical use thereof
WO2016073847A3 (en) Inhibitors of myocardin-related transcription factor and serum response factor (mrtf/srf)-mediated gene transcription and methods for use of the same
WO2013072921A3 (en) Process for preparation of substituted 3'-hydrazino-biphenyl-3-carboxylic acid compounds
EP3969111A4 (en) INHALABLE FORMULATIONS FOR KINASE INHIBITION
TN2018000090A1 (en) New imidazo[4,5-b]pyridine derivatives as dual dyrk1/clk1 inhibitors
MX2019001053A (es) Inhibidores de antigeno de la membrana especifico para la prostata (psma) quelados.
MX2020008498A (es) Derivados de sobetirome.
EA201891239A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX2020008076A (es) Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo.
EP3932425A4 (en) CANCER THERAPY USING A 3,5-DISUBSTITUTED ALKYNYL BENZENE COMPOUND AND AN IMMUNE CHECKPOINT INHIBITOR